<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00864305</url>
  </required_header>
  <id_info>
    <org_study_id>B-09237</org_study_id>
    <nct_id>NCT00864305</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Non-fasting Conditions</brief_title>
  <official_title>A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Non-fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the relative bioavailability of gabapentin 400 mg capsules (Purepac) with that of&#xD;
      NEURONTIN® 400 mg capsules (Parke-Davis) in healthy adult male subjects under non-fasting&#xD;
      conditions, and to compare the differences in plasma levels after dosing the test formulation&#xD;
      with and without food&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: Interventional Study Design: Single dose, randomized, three-period,&#xD;
      three-treatment, six-sequence crossover study under non-fasting conditions (test and&#xD;
      reference) and fasting (test) conditions&#xD;
&#xD;
      Official Title: A relative Bioavailability Food Challenge Study of Gabapentin 400 mg Capsules&#xD;
&#xD;
      Further study details as provided by Actavis Elizabeth LLC:&#xD;
&#xD;
      Primary Outcome Measures:&#xD;
&#xD;
      Rate and Extend of Absorption&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1997</start_date>
  <completion_date type="Actual">January 1998</completion_date>
  <primary_completion_date type="Actual">January 1998</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gabapentin 400 mg capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neurontin 400 mg capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin 400 mg capsules</intervention_name>
    <description>A: Experimental Subjects received Purepac formulated products under fed conditions</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Gabapentin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NEURONTIN® 400 mg capsules</intervention_name>
    <description>B: Active comparator Subjects received Parke-Davis's marketed product</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Gabapentin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin 400 mg capsules, single dose</intervention_name>
    <description>C: Experimental Subjects received Purepac formulated products under fasting conditions</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Gabapentin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All subjects selected for this study will be males 18 to 45 (inclusive) years of age.&#xD;
             Weight range of the subjects shall be 135-246 pounds, with individual weight variation&#xD;
             not more than 10% ± from normal for height and body frame (Metropolitan Life, 1983,&#xD;
             Height, Weight, Body Chart).&#xD;
&#xD;
          -  Each subject shall be given a general physical examination within 21 days of&#xD;
             initiation of the study. Such examination includes, but is not limited to, blood&#xD;
             pressure, general observations, and history.&#xD;
&#xD;
        At the end of the study, the subjects will have an exit evaluation consisting of interim&#xD;
        history, global evaluation, and clinical laboratory measurements.&#xD;
&#xD;
        Adequate blood and urine samples should be obtained within 21 days before beginning of the&#xD;
        first period and at the end of the trial for clinical laboratory measurements. Clinical&#xD;
        laboratory measurements will include the following:&#xD;
&#xD;
        Hematology: hemoglobin, hematocrit, red blood cell count, platelets, and white blood cell&#xD;
        count (with differential).&#xD;
&#xD;
        Clinical Chemistry: creatinine, BUN, glucose, SGOT, SGPT, bilirubin, and alkaline phosphate&#xD;
        Urine Analysis: pH, specific gravity, protein, glucose, ketones, bilirubin, occult blood,&#xD;
        and cells.&#xD;
&#xD;
        HTLV III Screen: (pre-study only) Hepatitis-B Surface Ag Screen: (pre-study only) Drugs of&#xD;
        Abuse Screen: (pre-study only) Subjects will be selected if all above are normal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a history of chronic alcohol consumption, drug addition, or serious&#xD;
             gastrointestinal, renal, hepatic or cardiovascular disease, tuberculosis, epilepsy,&#xD;
             asthma, diabetes, psychosis or glaucoma will not be eligible for this study.&#xD;
&#xD;
          -  Subjects whose clinical laboratory test values are greater than 20% outside the normal&#xD;
             range may be restricted. If the clinical values are outside the range on testing, the&#xD;
             subject will not be eligible to participate in the study unless the clinical&#xD;
             investigator deems the result to not be significant.&#xD;
&#xD;
          -  Subjects who have a history of allergic responses to the class of drug being tested&#xD;
             should be excluded from the study.&#xD;
&#xD;
          -  Subjects who use tobacco in any form will not be eligible to participate in the study.&#xD;
             Three months abstinence is required.&#xD;
&#xD;
          -  All subjects will have urine samples assayed for the presence of drugs of abuse as a&#xD;
             part of the clinical laboratory screening procedures. Subjects found to have urine&#xD;
             concentrations of any of the tested drugs will not be allowed to participate.&#xD;
&#xD;
          -  Subjects should not have donated blood and/or plasma for at least thirty (30) days&#xD;
             prior to starting the study.&#xD;
&#xD;
          -  Subjects who have taken any investigational drug within thirty (30) days prior to the&#xD;
             start of the study will not be allowed to participate.&#xD;
&#xD;
          -  Subjects who have been exposed to known hepatic enzyme inducting or inhibiting agents&#xD;
             within thirty (30) days prior to dosing will not be allowed to participate.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Siler, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cetero Research, San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gateway Medical Research, Inc</name>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2009</study_first_posted>
  <last_update_submitted>August 13, 2010</last_update_submitted>
  <last_update_submitted_qc>August 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Meena Venugopal, Director, Clinical R&amp;D</name_title>
    <organization>Actavis Inc</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Gabapentin</keyword>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

